Investigational drug · Phase 2
RBD5044
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dyslipidemias, Hypertriglyceridemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "RBD5044"
First trial start
2025
Jan 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RBD5044", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dyslipidemias
- Hypertriglyceridemia
Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "RBD5044" as an intervention, largest first.
- Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed DyslipidemiaPivotal-lookingRecruiting
Ribocure Pharmaceuticals ABIndustry
NCT06797401 · 120 participants (planned) · Start Jan 28, 2025 · Primary completion May 31, 2027
Drug: RBD5044; Placebo · For: Dyslipidemias
Sites: Krakow, Poland; Warsaw, Poland; Lund, Sweden · 6 sites in all
- A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044Completed
Suzhou Ribo Life Science Co. Ltd.Industry
NCT05539651 · 72 participants · Start Nov 10, 2022 · Primary completion Oct 30, 2024
Drug: RBD5044; Placebo · For: Health Volunteer
Sites: Brisbane, Australia
- RBD5044 in Chinese Participants With HypertriglyceridemiaActive, not recruiting
Ribotek Biopharmaceuticals (Shandong) Co., LtdIndustry
NCT07587788 · 40 participants (planned) · Start Feb 28, 2026 · Primary completion Mar 2027
Drug: RBD5044; Placebo · For: Hypertriglyceridemia
Sites: Daqing, China; Harbin, China; Luoyang, China · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model.
Tian Z, Luo H, Chu Y, et al. · Clin Pharmacokinet 2025
Also in development for Dyslipidemias
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.